The Effect of Donepezil on Wound Healing

NCT ID: NCT04505670

Last Updated: 2023-05-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-30
• Study Completion Date: 2023-07-30

Brief Summary

The purpose of the study is to test effectiveness of donepezil to improve wound healing in patients with diabetic wounds that have not healed with standard treatment.

Detailed Description

The study will be a randomized double blind study whereby patients with refractory diabetic wound healing over 3-6 months will be randomized to ascertain the effect of donepezil (administration of 5 mg to 10 mg of donepezil daily, orally, over 6 week period) on clinical wound healing reflecting correction of diabetic microvascular disease of non-healing wounds. The subjects will be recruited from the University of Maryland Shore Medical Center at Easton's emergency room and inpatients. Subjects will also be recruited from University of Maryland Shore Medical Group Wound Care and University of Maryland Baltimore Washington Medical Center's Vascular Clinic.

20 patients with Type 2 Diabetes Mellitus (Adult Onset Diabetes Mellitus) and non-healing ulcers/ wounds refractory to management with topical preparation and local debridement over a 3 to 6 month period prior will randomized to treatment or control group. The study group will be treated with oral donepezil (5 to 10 mg ). After 3 days of treatment, the dose of donepezil or placebo will be increased to 10 if no improvements are noted in skin integrity in the feet or lower extremity. Improvements in capillary refill and vascular edema will determine increase of donepezil from 5 to 10 mg. All patients will receive topical zinc oxide 20% topically three times a day, an effective topical management of diabetic wounds. Measurement of wound size and depth will be made prior to treatment. Additionally a color photograph will be obtained to compare with wound appearance in 6 weeks.

As many patients as required to meet the enrollment numbers shall be screened. Patients will be monitored daily for blood pressure, glucose levels and heart rate, during the period of hospitalization. Adjustments in insulin or oral hypoglycemic, blood pressure and heart rate control medications will occur during this time. Follow up visits will be made as required and at the end of week 6.

Donepezil shall be orally administered to the study group. Control group will get an orally administered placebo which is an inert compound, lactulose.

Wk0 will be the randomization visit. The patients will take the drug for 6 weeks and the last follow up visit will be the last day of week 6. Follow up at 6 weeks will occur at Shore Rehab at Easton.

Any anticholinergic drugs will be eliminated from the patients' medical regimen with the exception for inhaled anticholinergic. There is no known major contraindication of acetylcholinesterase inhibitors (like for eg: galantamine, rivastigmine and donepezil) Patients shall be monitored closely for vagotonic effect. Acetylcholine is known to have a vagotonic effect lowering heart rate and blood pressure. Therefore, during the course of administration of the drug close attention to heart rate and blood pressure will be a significant part off the clinical management of patients. If the patients are on beta blockers, their beta blocker dose will be closely monitored and adjusted as required.

H2 antagonist will be used to guard against any possible GI bleed, Pepcid 20mg a day.

Patient will be observed for seizures. The patients will be examined for pulmonary exacerbation during treatment in the hospital. If the pulmonary status deteriorates they will be eliminated from the study. The medication administration will not start sooner than 24 hrs after surgery. Patients shall be observed for exaggerated response from anesthesia.

Photographs of the diabetic wound/ ulcer and HgbA1C will be obtained on introduction to study and obtained at completion at 6 weeks.

Conditions

Wound Heal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Donepezil and Topical Zinc Oxide

donepezil 5mg daily and topical zinc oxide 20% three times daily

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

donepezil orally 5mg

Topical Zinc Oxide

Intervention Type: DRUG

Topical Zinc Oxide 20%

Placebo and Topical Zinc Oxide

Placebo daily and topical zinc oxide 20% three times daily

Group Type: PLACEBO_COMPARATOR

Placebo oral tablet

Intervention Type: DRUG

Placebo

Topical Zinc Oxide

Intervention Type: DRUG

Topical Zinc Oxide 20%

Interventions

Donepezil

donepezil orally 5mg

Intervention Type: DRUG

Placebo oral tablet

Placebo

Intervention Type: DRUG

Topical Zinc Oxide

Topical Zinc Oxide 20%

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• over the age of 20
• diagnosed with Diabetes Mellitus

Exclusion Criteria

• under the age of 20
• pregnant of lactating
• lactose intolerance
• allergy to donepezil
• prothrombin time and international normalized ratio value greater than 1.25
• Pre Menopausal women/ Women of childbearing potential

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Maryland, Baltimore

OTHER

Sponsor Role: lead

Responsible Party

Stephen Wills

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Maryland Shore Medical Center at Easton

Easton, Maryland, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Stephen Wills, MD

Role: primary

swills@umm.edu

410-822-1000

Other Identifiers

SH2019-8

Identifier Type: -

Identifier Source: org_study_id